Option chain shows key data for Vivos's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Vivos.

Vivos (OTC:RDGL) Stock, Option Chain

Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.

Penny,Stock,Investments,Taking,Off,Concept

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

PAPL

RDGL

VANI

Pineapple Financial And 1 Other Stock Under $1 Insiders Are Buying

Screenshot 2024-07-01 at 8.57.06 AM

Biotech

General

Vivos One Step Closer To Transforming Cancer Treatment With FDA Application To Start Human Trials For Pioneering Injectable Brachytherapy Device

Alset And 2 Other Stocks Under $2 Insiders Are Buying

Vivos Inc

WIIM

CETX

Cemtrex shares are trading lower after the company announced its board approved a 1-for-35 reverse stock split.

SCLX

Scilex shares are trading lower after the company announced it received a receipt of notice from Nasdaq for its failure to file its quarterly report ending September 30.

AFRM

Affirm Holdings shares are trading higher after B of A Securities maintained a Buy rating on the stock and raised its price target from $50 to $74.

DA Davidson analyst Michael Baker reiterated the Buy rating on BJ&#8217;s Wholesale Club Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>),<a target="_blank" href="https://www.benzinga.com/quote/BJ/analyst-ratings" rel="noreferrer noopener"> raising the price forecast to $110 from $95.</a>
Yesterday, the company reported third-quarter adjusted earnings per share of $1.18, beating the street view of 91 cents. Quarterly revenues of $5.10 billion were in line with the analyst consensus.
BJ&#8217;s Wholesale Club expects fourth-quarter adjusted EPS to be between $0.78 and $0.88. For FY2024, adjusted EPS is forecasted at $3.90 – $4.00, up from previous guidance for a low end of $3.75 – $4.00 and&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">against the consensus estimate of $3.85.</a>
The analyst notes that BJ has had another strong quarter, showing improvements in key areas like membership, sales, and digital performance.
BJ&#8217;s Wholesale Club expects fourth quarter comparable club sales, excluding gasoline, to rise 2.5% &#8211; 3.0% year-over-year.
With plenty of room to grow its store base, BJ&#8217;s is positioned as one of the rare long-term square footage growth stories in the big-box retail sector. Recent successes also allow BJ&#8217;s to raise fees, which, while benefiting customers, will ultimately be advantageous for shareholders, the analyst writes.
The analyst highlights BJ&#8217;s strategy to compete with Costco Wholesale by focusing on differentiating itself, especially in the grocery and fresh produce areas.
BJ&#8217;s grocery sales make up 77% of its total, compared to Costco&#8217;s 54%. Per Bake, BJ&#8217;s aims to replace weekly grocery trips, while Costco is more about stock-up shopping.
Their &#8220;Fresh 2.0&#8221; program, launched 18 months ago, improves perishable and produce offerings through supply chain investments, better vendor relations, and enhanced in-store experiences.
The program has shown positive results, with strong produce sales and customers spending more, leading to significantly higher annual spending, the analyst adds.
Price Action: BJ shares are trading higher by 3.78% to $96.30 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42142422/nano-labs-15-whats-going-on" target="_blank" rel="noreferrer noopener">Chinese Fabless Integrated Circuit Company Nano Labs Stock Skyrockets With New V Series Launch: Details</a></li>
</ul>

Analyst Color

Equities

Price Target

Reiteration

Analyst Ratings

COST

BJ's Wholesale Positioned As One Of Few Big-box Retailers With Long-Term Growth Potential – Analyst Highlights Membership, Sales, And Digital Performance

PDD Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) reported downbeat earnings for its fiscal third <a href="https://www.benzinga.com/quote/pdd/earnings">quarter 2024 on Thursday</a>.
The company posted revenue growth of 44% year-on-year to $14.16 billion (68.84 billion Chinese yuan), missing the analyst consensus estimate of $14.47 billion. The Chinese online retailer&#8217;s adjusted earnings per ADS of $2.65 (18.59 Chinese yuan) increased from 11.61 Chinese yuan Y/Y, missing the analyst consensus estimate of $2.82. The stock plunged after the print.
Revenues from online marketing services and others rose 24% Y/Y to $7.03 billion. Revenues from transaction services jumped 72% Y/Y to $7.13 billion.
Adjusted operating profit grew by 48% Y/Y to $3.81 billion. PDD Holdings held $44.0 billion in cash and equivalents as of September 30, 2024. The company generated $3.92 billion in operating cash flow.
&#8220;Over the past quarter, our focus remained on driving the high-quality development of the platforms,&#8221; said Mr. Lei Chen, Chairman and Co-Chief Executive Officer of PDD Holdings. &#8220;We are committed to investing consistently and patiently in our platform ecosystem to deliver impactful results over the long run.&#8221;
PDD shares fell 4.8% to trade at $99.06 on Friday.
These analysts made changes to their price targets on PDD following earnings announcement.
<ul>
<li>JP Morgan analyst Andre Chang downgraded PDD Holdings from Overweight to Neutral and lowered the price target from $170 to $105.</li>
<li>Benchmark analyst Fawne Jiang maintained PDD Holdings with a Buy and cut the price target from $185 to $160.</li>
<li>Jefferies analyst Thomas Chong, on Thursday, maintained PDD with a Buy and lowered the price target from $181 to $171.</li>
</ul>
Considering buying PDD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="616" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22134807/image-256-1024x616.png" alt="" class="wp-image-661567" style="width:726px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22134807/image-256-1024x616.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22134807/image-256-300x180.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22134807/image-256-768x462.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22134807/image-256.png 1097w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Earnings

Citigourp Global Markets 2% Protected Notes Linked To The Djia

These Analysts Slash Their Forecasts On PDD Holdings Following Q3 Results

At the recent <a href="https://cannabismarketspotlight.com/california/anaheim-november-12/">Cannabis Market Spotlight: California</a> event in Anaheim, DJ Saul, CEO of B&amp;Y Ventures, shared his perspective on the role of genuine connections in celebrity-backed cannabis brands. Representing Khalifa Kush, the cannabis line co-founded by Wiz Khalifa, Saul spoke about how an authentic brand connection can set companies apart in a competitive industry.
<h3 class="wp-block-heading">Building Trust Through Authentic Branding</h3>
"Khalifa Kush has the most authentic celebrity story in the space," Saul said, suggesting that this foundation has helped the brand resonate with consumers who value a true connection between the brand and its namesake.
Unlike many celebrity-driven ventures, Khalifa Kush reflects Khalifa&#8217;s personal values and public image, building a sense of trust and relatability with fans and customers.
<h3 class="wp-block-heading">Lessons from the Industry</h3>
During the panel, Saul also pointed to Planet 13's approach to celebrity involvement as a meaningful example. Lee Fraser of Planet 13 described their focus on bringing celebrity partnerships to life in real, engaging ways. Saul agreed that this approach helps create a strong and genuine connection with audiences.
Reflecting on audience reactions during the discussion, Saul noted that "a lot of heads [were] nodding out there," indicating broad agreement among attendees about the importance of real connections in brand development.
Saul's comments highlight an approach that many in the cannabis industry are now focusing on—authentic celebrity-driven branding that goes beyond mere endorsements. 
Khalifa Kush's model suggests that genuine, aligned involvement from a brand's celebrity founder can foster loyalty and credibility, distinguishing it from others in the field.
Image: Wiz Khalifa Duki

Cannabis

Events

Exclusives

Interview

'The Most Authentic Celebrity Story In Cannabis': Khalifa Kush Exec

American Airlines Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NYSE">AAL</a>) short percent of float has fallen 18.74% since its last report. The company recently reported that it has 66.51 million shares sold short, which is 11.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.89 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>American Airlines Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732301121_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for American Airlines Gr has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing American Airlines Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, American Airlines Gr's peer group average for short interest as a percentage of float is 9.08%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into American Airlines Gr's Recent Short Interest

Cigna's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) short percent of float has risen 22.55% since its last report. The company recently reported that it has 3.45 million shares sold short, which is 1.25% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.54 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cigna Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732301116_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cigna has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cigna's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cigna's peer group average for short interest as a percentage of float is 8.26%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Cigna's Recent Short Interest

Moderna's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NYSE">MRNA</a>) short percent of float has risen 3.25% since its last report. The company recently reported that it has 34.38 million shares sold short, which is 11.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.68 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Moderna Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732301111_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Moderna has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Moderna's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Moderna's peer group average for short interest as a percentage of float is 4.72%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MRNA

Looking Into Moderna's Recent Short Interest

Several analysts expressed views on Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) third-quarter results reported on Thursday.
The company reported EPS&nbsp;of $1.48, exceeding the consensus of $1.40, while sales&nbsp;of $5.07 billion <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42123039/ross-stores-reports-third-quarter-earnings-updates-fourth-quarter-guidance" rel="noreferrer noopener">missed the street view of&nbsp;$5.15 billion</a>.
Ross Stores expects fourth-quarter EPS of&nbsp;$1.57 &#8211; $1.64&nbsp;versus consensus of $1.67 and FY25 EPS&nbsp;of $6.10 &#8211; $6.17&nbsp;compared <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">to the street view of $6.14</a>.
BofA Securities analyst Lorraine Hutchinson reiterated a <a target="_blank" href="https://benzinga.com/quote/ROST/analyst-ratings" rel="noreferrer noopener">Buy rating on the stock with a price target of $180.</a>
The analyst writes that the company&#8217;s value-focused offerings continue to appeal to stretched consumers.
The analyst says the fourth-quarter guidance accounts for a timing shift in packaway expenses (benefiting the third quarter by $0.03) and lapping last year&#8217;s extra week, which added $0.20 to EPS and 80 basis points to OM. Hutchinson adjusted the FY24 estimate to $6.14, up 1%.
Telsey Advisory Group analyst Dana Telsey reaffirmed the Market Perform rating with a price target of $175.
The analyst writes that Ross Stores&#8217; earnings beat reflected margin tailwinds, despite topline results falling short of expectations. While some sales weakness was attributed to unfavorable weather, product assortment issues also contributed, failing to fully capture consumer interest.
Looking ahead, the company remains aware of the challenging macroeconomic environment, particularly for its low-to-moderate income demographic, which faces pressure from rising essential costs, says the analyst.
The analyst writes that although FY24 EPS guidance was raised, fourth-quarter projections fell short, underscoring persistent challenges.
Ross&#8217;s commitment to value continues to attract deal-seeking customers, but macroeconomic uncertainty and the price sensitivity of its core demographic weigh, adds the analyst.
Guggenheim analyst Robert Drbul maintained a Buy rating with a $180 price target.
The analyst says that while macro uncertainties remain, he expects Ross to sustain positive sales momentum this holiday season, driven by strength in gifting, cosmetics, and accessories, and carry this into 2025.
Drbul sees EPS estimates of $6.15 in FY24 and $6.70 in FY25, which reflects a favorable environment for Ross, supported by ample branded goods supply, a strong value proposition, and ongoing sales optimism.
Following the third-quarter revenue miss, the analyst slightly reduced the FY24 revenue forecast, factoring in persistent inflation and its impact on discretionary spending.
Goldman Sachs analyst Brooke Roach writes that they remain positive on Ross Stores. Despite weather-related comp softness and execution challenges, ROST&#8217;s strategy of offering branded value merchandise at sharper prices is gaining traction.
While this pressures merchandise margins, operational efficiencies have offset the impact. Management acknowledges ongoing macro pressures on low- to middle-income consumers but expects sequential strength in the holiday quarter, driven by gifting and seasonal items, adds the analyst.
Roach writes that additional catalysts include the appointment of a new <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41586044/ross-stores-names-james-g-conroy-as-next-chief-executive-officer" rel="noreferrer noopener">CEO, effective February 2025</a>.
The analyst revised the FY24, FY25, and FY26 EPS estimates to $6.19, $6.54, and $7.14 (from $6.07, $6.47, and $7.06), respectively, to account for the quarterly results, timing adjustments, and slight margin forecast updates.
BMO Capital Markets analyst Simeon Siegel kept the Outperform rating and a price target of $168.
The analyst writes that ROST delivered a bottom-line beat, driven by stronger-than-expected gross margins, despite a topline miss attributed to unfavorable weather.
Management lowered its fourth-quarter EPS guidance but reiterated comp expectations, slightly raising the FY EPS high-end by $0.03, which the analyst views as conservative.
Investors can gain exposure to the stock via Virtus ETF Trust II Virtus KAR Mid-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMID#NYSE">KMID</a>) and VanEck Retail ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTH#NASDAQ">RTH</a>).
Price Action: ROST shares are up 2.41% at $146.41 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42139806" target="_blank" rel="noreferrer noopener">EchoStar Shares Sink As DirecTV Terminates Acquisition Agreement</a></li>
</ul>

Large Cap

Movers

Virtus ETF Trust II Virtus KAR Mid-Cap ETF

KMID

ROST

Merrill Lynch Retail HOLDRS Trust due 12/31/41

Analysts See Growth Potential In Ross Stores Amid Holiday Season Optimism: Details

Macro Economic Events

Market Summary

Economics

$BTC

Benzinga Market Summary: Bitcoin Approaches $100K, S&P Rises

ALLY

Ally Financial Weighs Sale Of Credit Card Business

The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) reported better-than-expected earnings for its second quarter and <a href="https://www.benzinga.com/quote/GAP/earnings">raised its outlook for FY24 gross margin.</a>
Gap reported quarterly earnings of 72 cents per share, which beat the analyst consensus estimate of 57 cents. Quarterly revenue came in at $3.82 billion, which beat the consensus estimate of $3.81 billion and is an increase over sales of $3.76 billion from the same period last year.
"I'm proud that Gap Inc. delivered another successful quarter, growing net sales for the fourth consecutive quarter and gaining market share across all brands while meaningfully expanding operating margin," said Gap CEO Richard Dickson.
Gap raised its full-year outlook for net sales, gross margin and operating income growth compared to prior expectations. The company now sees net sales up 1.5% to 2%, gross margin growth of 220 basis points and operating income margin of mid-to-high 60%.
Gap shares gained 10.7% to trade at $24.41 on Friday.
These analysts made changes to their price targets on Gap following earnings announcement.
<ul>
<li>B of A Securities maintained Gap with a Neutral and raised the price target from $25 to $28.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/62a9ca40b9d3b0000138d981/alex-straton">Morgan Stanley analyst Alex Straton</a> maintained Gap with an Overweight and raised the price target from $29 to $30.</li>
<li>Barclays analyst Adrienne Yih maintained the stock with an Overweight and raised the price target from $31 to $32.</li>
<li>Wells Fargo analyst Ike Boruchow maintained Gap with an Overweight and raised the price target from $28 to $30.</li>
<li>Evercore ISI Group analyst Michael Binetti maintained the stock with an Outperform and increased the price target from $32 to $33.</li>
<li>JP Morgan analyst Matthew Boss maintained Gap with a Neutral and boosted the price target from $26 to $28.</li>
<li>BMO Capital analyst Simeon Siegel maintained Gap with a Market Perform and raised the price target from $23 to $25.</li>
<li>Considering buying GAP stock? Here&#8217;s what analysts think: </li>
</ul>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="540" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22133942/image-255-1024x540.png" alt="" class="wp-image-661553" style="width:664px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22133942/image-255-1024x540.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22133942/image-255-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22133942/image-255-768x405.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22133942/image-255.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

These Analysts Increase Their Forecasts On Gap Following Better-Than-Expected Earnings

Needham analyst Tom Nikic initiated Nike, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Buy rating and a<a target="_blank" href="https://www.benzinga.com/quote/NKE/analyst-ratings" rel="noreferrer noopener"> price forecast of $84.</a>
The analyst suggests that Nike&#8217;s worst may nearly be over, with the recent CEO transition from John Donohoe to Nike veteran Elliott Hill seen as a major turning point &#8211; &#8220;Nike&#8217;s proverbial white knight.&#8221;
The analyst also acknowledges that management accepts past mistakes and takes decisive steps to correct them.
Although these strategies may pressure profits on P&amp;L in the short term, they are viewed as the right moves for the company, Nikic writes.
While rebuilding the brand&#8217;s momentum will take time, the analyst sees potential for Nike to become an attractive &#8220;story stock&#8221; in 2025, especially if performance has hit its lowest point and investors view Elliott Hill as the company&#8217;s savior.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/42143421/staggering-google-breakup-proposal-from-doj-a-kitchen-sink-moment-alphabet-analyst" rel="noreferrer noopener">&#8216;Staggering&#8217; Google Breakup Proposal From DOJ A &#8216;Kitchen Sink Moment&#8217;: Alphabet Analyst</a>
The analyst notes that three years ago, the consensus FY25 EPS forecast for Nike was around $6.60, but it has now dropped to $2.75.
However, per Nikic, this updated estimate accurately reflects the necessary adjustments Nike needs to make.
The analyst also projects revenue declines to peak in the second half of 2024 and the first half of 2025 as Nike reduces over-distributed styles.
If revenue trends improve in the coming quarters and the EPS revision cycle turns positive, the analyst forecasts Nike&#8217;s stock could start rising.
The analyst projects Nike to report FY25 revenues of $47.383 billion, with earnings per share of $2.67.
Price Action: NKE shares are trading higher by 2.52% to $76.99 at last check Friday.
Photo via Shutterstock
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks" target="_blank" rel="noreferrer noopener">Trump Appears &#8216;Frustrated&#8217; As Elon Musk Chimes In On Treasury Secretary, Adds More Names To Short List </a></li>
</ul>

Initiation

Nike's Worst May Nearly Be Over: Analyst Sees CEO Transition And Strategic Fixes Sparking A Turnaround

U.S. small-cap stocks have delivered an <a href="https://www.benzinga.com/partner/markets/24/11/42086831/how-the-intersection-of-public-health-and-politics-can-shift-the-societal-landscape">exceptional performance this November</a>, with the iShares Russell 2000 ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NASDAQ">IWM</a>) climbing 8.5% and outpacing the SPDR S&amp;P 500 ETF Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NASDAQ">SPY</a>).
This year's rally for IWM is driven by supportive monetary policy, political developments, and economic resilience. The Federal Reserve's recent rate cuts, including a 25-basis-point reduction in November, have reduced borrowing costs, particularly benefiting small-cap companies that rely heavily on credit.
What To Know: Small-cap companies, which constitute the bulk of the Russell 2000 index, are typically more sensitive to borrowing costs than their larger counterparts.
Unlike large-cap companies, which often have diversified funding sources and international revenue streams, small-caps rely heavily on domestic lending to finance operations, expansion and innovation.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42140842/sp-500-faces-volatile-2025-as-inflation-boom-could-return-bank-of-america-strategist">S&amp;P 500 Faces Volatile 2025 As &#8216;Inflation Boom&#8217; Could Return: Bank Of America Strategist</a>
Lower interest rates directly reduce borrowing costs, improving profit margins for small-cap firms. Additionally, cheaper credit can enable these businesses to invest more aggressively in growth initiatives, such as hiring, capital expenditures and research and development.
Rate cuts also typically encourage a rotation into riskier assets like small caps, as the lower yields on fixed-income securities push investors to seek higher returns in equities. This shift in investor sentiment is another factor behind the strong performance of IWM during periods of monetary easing.
What Else: Optimism surrounding the Republican sweep in the 2024 elections has further bolstered small caps, as investors anticipate <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">regulatory rollbacks</a>.
Economic fundamentals have added fuel to the rally. The U.S. economy remains strong, with <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41631465/us-gdp-rises-2-8-in-q3-but-can-the-momentum-last-what-6-top-economists-are-saying">steady GDP growth</a> and a robust labor market supporting consumer confidence and domestic demand, key drivers for small-cap stocks.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42141413/us-business-activity-soars-to-31-month-highs-in-november-small-caps-rally-dow-tops-44000">US Business Activity Soars To 31-Month Highs In November: Small Caps Rally, Dow Tops 44,000</a>
<h2 class="wp-block-heading">IWM Performance After Recent Elections</h2>
Historical data from <a href="https://www.benzinga.com/pro/register?gspk=bHVrZWphY29iaTUzNDg&amp;gsxid=EfCj4A0Ti3Vk">Benzinga Pro</a> suggests that the performance of small caps, including IWM, often reflects broader market sentiment driven by post-election policies, economic expectations and seasonal trends.
<ul>
<li>November 2020 (Post-Biden Election): Following the election of Joe Biden, IWM experienced a sharp rally, increasing by 18.24% in November 2020. This surge was largely driven by investor optimism surrounding the COVID-19 vaccine and the possibility of new fiscal stimulus​.​ </li>
<li>November 2016 (Post-Trump Election): After Donald Trump won the election in November 2016, IWM rose by approximately 6.5%. This was fueled by expectations of pro-business policies, including tax cuts and deregulation​. </li>
<li>November 2012 (Post-Obama Re-election): In November 2012, after President Obama was re-elected, IWM saw more modest growth, rising by about 1.5%. This reflected investor expectations of stability under Obama's second term​. </li>
<li>November 2008 (Post-Obama's First Election): Following Barack Obama's first election, small-cap stocks faced challenges in the aftermath of the financial crisis. IWM declined by approximately 5% in November 2008 as the market struggled amid the global economic downturn​.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/tech/24/11/42140450/doj-targets-google-chrome-poll-shows-64-oppose-alphabet-breakup-youtube-seen-as-top-prize">DOJ Targets Google Chrome, Poll Shows 64% Oppose Alphabet Breakup: YouTube Seen As Top Prize</a>

What's Driving Small-Cap Success For iShares Russell 2000 ETF (IWM) In November?

Risk appetite remained robust in the final trading session of the week, with all major U.S. indices poised to close the week in positive territory. Small-cap stocks outperformed their large-cap counterparts, continuing their <a href="https://www.benzinga.com/news/small-cap">recent streak of dominance</a>.
Fresh business surveys highlighted a notable health in the U.S. economy, with private sector activity recording its strongest expansion in over two and a half years. The services sector, in particular, showed remarkable growth, maintaining its rapid pace of expansion.
The Russell 2000, a benchmark for small-cap equities, surged 1.7% on Friday, building on a 1.5% gain from the previous session. The S&amp;P 500 edged higher, heading for a five-day winning streak, and the Dow Jones Industrial Average climbed past the 44,000 mark, moving tantalizingly close to record highs. Technology stocks posted more modest gains.
The U.S. Dollar Index, tracked via the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), extended its rally for an eighth consecutive week—the longest streak in 14 months—surpassing the 107 level to hit a two-year high. The dollar's strength was fueled by a mix of robust U.S. economic data <a href="https://www.benzinga.com/news/econ-s/24/11/42138717/dollar-hits-2-year-highs-as-europes-recession-signals-spark-euro-pound-sell-offs">and economic malaise in Europe.</a>
In commodities, gold climbed for a fifth straight session, advancing 5.6% for the week, its best weekly performance since March 2023.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) also maintained its bullish momentum, soaring past $99,000 and edging closer to the highly anticipated $100,000 milestone. 
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,401.00</td>
<td>1.7%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,211.20</td>
<td>0.8%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,969.01</td>
<td>0.4%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,768.99</td>
<td>0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:05 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent111924&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.4% to $595.75.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 0.8% to $442.49.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) inched 0.2% up to $506.20.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 1.8% to $238.61.</li>
<li>The&nbsp;Consumer Discretionary Sector Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, rising 1.6%. The&nbsp;Utilities Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 0.1%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
<ul>
<li>Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) fell 4.4% in reaction to quarterly earnings. </li>
<li>Other stocks reacting to earnings reports were Copart Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>), up 9.8%, Ross Stores Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROSS#NASDAQ">ROSS</a>), up 3.1%, and NetApp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>), down 2.7%. </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42140842/sp-500-faces-volatile-2025-as-inflation-boom-could-return-bank-of-america-strategist">S&amp;P 500 Faces Volatile 2025 As &#8216;Inflation Boom&#8217; Could Return: Bank Of America Strategist</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Broad U.S. Equity ETFs

Commodities

Econ #s

Tech

ETFs

CPRT

SPDR Dow Jones Industrial Average ETF Trust

INTU

NTAP

ROSS

PowerShares DB US Dollar Index Bullish Fund

Select Sector SPDR-Consumer Discretionary

Small Caps Rally, Gold Poised For Best Week Since March 2023, Bitcoin Tops $99,000: What's Driving Markets Friday?

StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) shares are moving higher on Friday after the company announced a share repurchase plan. Here&#8217;s what <a href="https://www.benzinga.com//node/42132115">you need to know</a>.
What To Know: Under the plan, Stone plans to repurchase shares worth up to R$ 2 billion ($344.6 million).
The repurchase plan will replace its previous program, announced last year, in which Stone repurchased a total of 13,202,939 shares at an average price of R$ 20.45 per share, totaling R$ 1.03 billion.
&#8220;We are pleased to announce the completion of our previous R$1 billion share repurchase program, underscoring our robust financial position. As part of our ongoing commitment to maximizing shareholder returns, we continuously evaluate the most effective use of our resources,&#8221; said Pedro Zinner, CEO.
&#8220;Confident in our long-term vision, we have approved a new buyback program to seize the current market opportunities. Furthermore, we are finalizing a structured framework to guide our capital allocation strategy, which will enhance transparency and align with our strategic priorities once shared with the market.&#8221;
How To Buy StoneCo Shares
By now you're likely curious about how to participate in the market for StoneCo &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stocks, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the case of StoneCo, which is trading at $10.29 as of publishing time, $100 would buy you 9.72 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42122886/cathie-woods-3-8-million-bitcoin-vision-met-with-doubt-83-say-not-by-2030">Cathie Wood&#8217;s $3.8 Million Bitcoin Vision Met With Doubt: 83% Say Not By 2030</a>
STNE Price Action: At the time of writing, StoneCo stock is trading 12.2% higher at $10.41, per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Image via Pixabay

STNE

What's Going On With StoneCo Stock Friday?

CV Sciences, Inc. (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTCQB">CVSI</a>) a hemp-focused wellness company announced on Thursday it's acquiring Extract Labs, Inc., a manufacturer and distributor of premium cannabinoid products including gummies, topicals and tinctures.
<h3 class="wp-block-heading">What Happened</h3>
The company noted that it has entered into a definitive agreement to purchase Extract Labs for the following considerations:
<ul>
<li>cash payment of $400,000, less the amount of certain holdbacks and adjustments; and</li>
<li>the issuance of shares of&nbsp;CV Sciences&#8217; common stock valued at $1 million based on the sixty-day volume weighted average price of CV Sciences&#8217; common stock.</li>
</ul>
Additionally, under the deal, Extract Labs sellers will be eligible to receive up to $600,000 of additional shares of CV Sciences&#8217; common stock if Extract Labs satisfies certain revenue targets during the first year following the closing date.
Read Also: <a href="https://www.benzinga.com/24/11/41992549/cv-sciences-q3-revenue-stable-amid-new-launches-financing">CV Sciences Q3: Revenue Stable Amid New Launches, Financing</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Why It Matters</h3>
Extract Labs' branded products are sold through a range of sales channels from business-to-business (B2B) to business-to-consumer (B2C).
Moreover, Extract Labs, which is GMP-certified and FDA-registered, has operational flexibility that allows for low to large minimum order quantity production runs, making the use of capital and the ability to increase speed to market for new product development more efficient.
CV Sciences says it expects the transaction will create the opportunity to increase its sales to current and new clients.
"The acquisition synergies are expected to increase our revenue and customer base, allow us to leverage our key assets, optimize operations and processes, and drive long-term growth and shareholder value," said CEO Joseph Dowling. "Extract Labs is a stand-alone profitable business and our plan is to increase its existing revenue base and further leverage its existing capacity."
<h3 class="wp-block-heading">What's Next</h3>
The acquisition is expected to close during the first quarter of 2025, subject to customary conditions precedent. The company also plans to in-source production of certain of its key products.
"We are planning to in-source the manufacturing of select +PlusCBD branded products providing an opportunity for meaningful cost savings. Extract Labs manufacturing capability will provide us with greater control over our supply chain and accelerate our new product development cycle,&#8221; Dowling said.
<h3 class="wp-block-heading">CVSI Price Action</h3>
CV Sciences' shares traded 9.09% lower at $0.04 per share after the market close on Thursday afternoon.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40344002/hemp-focused-cv-sciences-reports-flat-revenue-and-over-8-yoy-increase-in-gross-profit-in-q2">Hemp-Focused CV Sciences Reports Flat Revenue And Over 8% YoY Increase In Gross Profit In Q2</a></li>
</ul>

CVSI

Hemp-Focused CV Sciences Expands Via New Cannabis Acquisition, Here's What Investors Need To Know

<a href="https://www.federalreserve.gov/newsevents/pressreleases/monetary20241122a.htm" title="https://www.federalreserve.gov/newsevents/pressreleases/monetary20241122a.htm">https://www.federalreserve.gov/newsevents/pressreleases/monetary20241122a.htm</a>

Federal Reserve

Fed Announces Details For Coming Framework Review, Including May 15-16, 2025, Conference; Framework Review Will Not Include 2% Inflation Goal; To Focus On Statement Of Strategy And Communications Tools; Review Will Include Public "Fed Listens" Events Around The Country, Debate Among Policymakers To Commence At January Meeting

Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) reported better-than-expected third-quarter EPS <a href="https://www.benzinga.com/quote/rost/earnings">results on Thursday</a>.
Ross Stores reported quarterly earnings of $1.48 per share which beat the analyst consensus estimate of $1.40 per share. The company reported quarterly sales of $5.07 billion which missed the analyst consensus estimate of $5.15 billion.
Barbara Rentler, Chief Executive Officer, commented, &#8220;We are disappointed with our third quarter sales results as business slowed from the solid gains we reported in the first half of 2024. Although our low-to-moderate income customers continue to face persistently high costs on necessities pressuring their discretionary spending, we believe we should have better executed some of our merchandising initiatives. In addition, a combination of severe weather during the quarter from Hurricanes Helene and Milton, along with unseasonably warm temperatures, also negatively impacted our results.&#8221;
The company said it sees FY25 earnings of $6.10 to $6.17 per share.
Ross Stores shares gained 2.7% to trade at $146.80 on Friday.
These analysts made changes to their price targets on Ross Stores following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/593aad8085b07a000196219e/michael-binetti">Evercore ISI Group analyst Michael Binetti</a> maintained Ross Stores with an Outperform and raised the price target from $170 to $180.</li>
<li>JP Morgan analyst Matthew Boss maintained the stock with an Overweight rating and boosted the price target from $171 to $173.</li>
<li>Telsey Advisory Group analyst Dana Telsey maintained Ross Stores with a Market Perform and maintained a $175 price target.</li>
<li>Guggenheim analyst Robert Drbul reiterated Ross Stores with a Buy and maintained a $180 price target.</li>
</ul>
Considering buying ROST stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="556" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22133059/image-254-1024x556.png" alt="" class="wp-image-661536" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22133059/image-254-1024x556.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22133059/image-254-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22133059/image-254-768x417.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22133059/image-254.png 1238w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42139477/this-hca-healthcare-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-friday">This HCA Healthcare Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday</a></li>
</ul>

Ross Stores Analysts Boost Their Forecasts After Upbeat Earnings

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
I cannot stress enough how risky OTC stocks or securities traded over the counter really are. For one thing, just the name OTC should ring some alarm bells. This designation means that these securities don&rsquo;t trade on exchanges like the New York Stock Exchange or the Nasdaq. Instead, they trade via broker-dealer networks. And not all stock platforms support what&rsquo;s otherwise known as the pink sheets.



Second, many investors are shocked to discover the administrative costs tied to OTC stocks. Yes, many of these securities are &ldquo;cheap,&rdquo; trading hands at unit prices well below a buck. However, that doesn&rsquo;t mean that it&rsquo;s cheap to you. Wide bid-ask spreads may mean that your holdings may have to rise significantly higher to be net profitable. Also, even if you are profitable, low trading volume could mean a long time to find a buyer.



At the same time, OTC stocks or otherwise highly speculative shares can fly higher. Some <a href="https://www.gobankingrates.com/investing/stocks/most-successful-penny-stocks-ever/">examples</a> include the following:



<ul><li>Monster Beverage (NASDAQ:<a href="https://investorplace.com/stock-quotes/mnst-stock-quote/">MNST</a>): In 1997, you could have had MNST for just two cents.</li>



<li>Apple (NASDAQ:<a href="https://investorplace.com/stock-quotes/aapl-stock-quote/">AAPL</a>): On a split-adjusted basis, you could have bought AAPL for 10 cents in December 1980.</li>



<li>Advanced Micro Devices (NASDAQ:<a href="https://investorplace.com/stock-quotes/amd-stock-quote/">AMD</a>): Back in June 2015, AMD traded for below $2.</li>
</ul>Of course, there are way more failures than successes. But if you want to go for gold, below are the OTC stocks to consider.



<h2>Tencent (TCEHY)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/tcehy-stock-3-300x169.jpg" alt="Tencent (TCEHY) sign on Tencent headquarters in Shenzhen, China."><div>Source: StreetVJ / Shutterstock.com</div></div>


A Chinese multinational technology conglomerate, Tencent (OTCMKTS:<a href="https://investorplace.com/stock-quotes/tcehy-stock-quote/">TCEHY</a>) has had a rough outing in 2023. Mainly, that&rsquo;s due to the challenging circumstances surrounding the Chinese economy. And if a CNN report proves correct, 2024 <a href="https://www.cnn.com/2023/12/27/economy/china-economy-challenges-2024-intl-hnk/index.html">could be an even rougher outing</a>. Still, Tencent&rsquo;s <a href="https://www.reuters.com/technology/tencent-reveals-most-ambitious-game-yet-consoles-amid-global-expansion-2023-12-08/">expansionary ambitions</a> reach beyond its home nation. With eyes on Japan, South Korea, Southeast Asia, and <a href="https://www.prnewswire.com/apac/news-releases/tencent-cloud-highlights-collaborative-global-expansion-with-digital-ecological-partners-at-tencent-cloud-digital-ecosystem-summit-2023-global-connect-session-301921841.html#:~:text=Fred%20Sun%2C%20General%20Manager%20of,East%2C%20providing%20solutions%20for%20various">several other international regions</a>, Tencent could be interesting for speculators.



To be sure, with a market capitalization of around $337.5 billion, TCEHY doesn&rsquo;t exactly rate as one of the typical OTC stocks. However, it&rsquo;s a great confidence booster because it&rsquo;s in some ways the best of both worlds: offering tremendous upside potential while also being a technology stalwart in its home nation.



Analysts rate shares a <a href="https://www.tipranks.com/stocks/tcehy">consensus moderate buy</a> with a $49.56 average price target. That implies an upside potential of over 40%. What&rsquo;s more, the high-side target hits $61.13, possibly delivering growth of over 73%. If that wasn&rsquo;t enough to whet your appetite, shares <a href="https://www.gurufocus.com/stock/TCEHY/summary?search=tcehy">trade at only 13.06X forward earnings</a>, below the interactive media sector&rsquo;s median value of 21.19X.



<h2>BYD (BYDDF)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/byddf-stock-1-300x169.jpg" alt="A close-up view of the power supply plugged into a vehicle from BYD Company (BYDDY)."><div>Source: J. Lekavicius / Shutterstock.com</div></div>


Moving on to another Chinese company, BYD (OTCMKTS:<a href="https://investorplace.com/stock-quotes/byddf-stock-quote/">BYDDF</a>) presents a unique proposition. First, it&rsquo;s a major automotive enterprise specializing in electric vehicles, yet it technically ranks among the OTC stocks. Second, Warren Buffett &ndash; who is best known for investing in reliable blue chips &ndash; <a href="https://www.cnbc.com/berkshire-hathaway-portfolio/">owns BYD</a> via Berkshire Hathaway (NYSE:<a href="https://investorplace.com/stock-quotes/brk-b-stock-quote/">BRK-B</a>). To be fair, Buffett has been <a href="https://apnews.com/article/berkshire-hathaway-warren-buffett-byd-397410cefd128f283c5efcc7cf90c1fa">reducing his exposure</a> but he still owns a sizable amount.



Despite the seemingly contradictory tone, investors may want to consider adding BYDDF to their portfolio. Yeah, it&rsquo;s one of the OTC stocks and yes, the Chinese economy looks rather putrid if I&rsquo;m being honest. However, with EVs becoming increasingly commoditized, guess who&rsquo;s going to win that battle? There&rsquo;s just no way that western nations can compete with their higher labor costs.



Also, investors should consider another element: demand. European politicians may want to reduce the flood of Chinese EVs. But their constituents? They love &lsquo;em. So do analysts, who rate BYDDF a <a href="https://www.tipranks.com/stocks/byddf/forecast">consensus strong buy</a> with a $36.03 price target. That implies 63% upside potential.



<h2>Xiaomi (XIACF)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/05/electric-vehicle-charger1600-300x169.png" alt="Power supply connect to electric vehicle for charge to the battery. Charging technology industry transport which are the futuristic of the Automobile. EV fuel Plug in hybrid car."><div>Source: buffaloboy / Shutterstock.com</div></div>


Yet one more Chinese company to discuss and then we&rsquo;ll get into the really wild OTC stocks. A designer and manufacturer of consumer electronics and related software, Xiaomi (OTCMKTS:<a href="https://investorplace.com/stock-quotes/xiacf-stock-quote/">XIACF</a>) is a cynical play. For example, beyond its consumer electronics business, it&rsquo;s also involved in the EV space. Recently, the company <a href="https://www.cnbc.com/2023/12/28/chinas-xiaomi-unveils-first-ev-in-bid-to-compete-with-porsche-tesla.html">launched its first electric-powered vehicle</a>, which might have caught the eyes of some lawyers.



I&rsquo;m joking there, but seriously, the <a href="https://www.mi.com/global/discover/article?id=3095&amp;ref=upstract.com">Xiaomi SU7</a> looks like it ripped off the design of a particular German brand. But if the consumers who love BYD offer any clues, the SU7 should be a hit. Apparently, it has the performance (<a href="https://www.topspeed.com/xiaomi-su7-ev-facts/#:~:text=Performance%20Specifications&amp;text=The%20SU7%20Max%20trim%20will,top%20speed%20of%20165%20mph.">up to 664 horsepower</a>) and the longevity to <a href="https://www.carscoops.com/2023/12/xiaomis-su7-will-outrun-a-taycan-and-outlast-a-tesla-model-s/">better the top players in the ecosystem</a>. And even if you didn&rsquo;t like the EV pivot, Xiaomi should win in consumer electronics.



Frankly, with smart devices becoming so commoditized, people may start looking to price more often than brand. If so, XIACF has a clear pathway to robust shareholder profits. Analysts agree, rating the stock a <a href="https://www.tipranks.com/stocks/xiacf/forecast">unanimous strong buy</a> with a $2.66 average price target.



<h2>Quisitive Technology Solutions (QUISF)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/cloud1600d-300x169.jpg" alt=""><div>Source: Shutterstock</div></div>


Okay, let&rsquo;s buckle up for some serious OTC stocks and by that, I mean high risk, high reward. First, Quisitive Technology Solutions (OTCMKTS:<a href="https://investorplace.com/stock-quotes/quisf-stock-quote/">QUISF</a>) bills itself as a premier global Microsoft (NASDAQ:<a href="https://investorplace.com/stock-quotes/msft-stock-quote/">MSFT</a>) partner that harnesses its cloud platforms and complete technologies to generate transformational impact for midsize and enterprise-level customers. It&rsquo;s an intriguing idea because, at one point, shares closed at $1.54 on a weekly average basis.



Currently, QUISF trades hands at only 22 cents. And you should note that over the past 52 weeks, it lost more than 53% of its equity value. Further, according to the security&rsquo;s point-and-figure (P&amp;F) chart, it prints a double bottom breakdown. According to StockCharts.com&rsquo;s educational section, this pattern is a bearish signal. That said, the pattern should also be viewed in a <a href="https://school.stockcharts.com/doku.php?id=chart_analysis:pnf_charts:pnf_bearish_bd#:~:text=for%20price%20objectives.-,Double%20Bottom%20Breakdown,These%20patterns%20are%20not%20contradictory.">broader context</a> due to possible whipsaw effects.



And what is that context? Basically, the broader cloud computing market <a href="https://www.fortunebusinessinsights.com/cloud-computing-market-102697">could be worth $2.43 trillion</a> by 2030. Quisitive just needs to take a bite out of this market to potentially drive higher. Analysts seem to be on the same page, pegging the <a href="https://www.tipranks.com/stocks/quisf/forecast">average price target at 49 cents</a>.



<h2>Peninsula Energy (PENMF)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/uranium1600-300x169.jpg" alt="periodic table concept with black cubes. uranium element is glowing. Uranium stocks"><div>Source: Shutterstock</div></div>


As a fan of the uranium energy space, I perked up when I came across this opportunity hidden among OTC stocks. As a uranium extraction specialist, Peninsula Energy (OTCMKTS:<a href="https://investorplace.com/stock-quotes/penmf-stock-quote/">PENMF</a>) addresses a critical supply shortage that recently sprouted. According to The Wall Street Journal, last month, <a href="https://www.wsj.com/finance/commodities-futures/uranium-prices-jump-to-16-year-high-on-supply-woes-analysis-05c7086f">uranium prices jumped to a 16-year high</a> after one of the world&rsquo;s largest producers &ndash; Kazakhstan&rsquo;s state-owned company Kazatomprom &ndash; warned of production target shortfalls.



With uranium supplies uncertain for the next two years, several uranium players have skyrocketed. One of the exceptions is PENMF. In the trailing one-year period, the security declined by 8%. That said, it is up 15% on a year-to-date basis but that&rsquo;s a modest performance compared to exchange-listed uranium specialists.



Still, as far as OTC stocks are concerned, Peninsula could be intriguing because of geopolitical considerations. Basically, it features 100% ownership of the Lance Project, which is one of the largest uranium projects in the U.S.



Better yet, analysts expect great things, pegging shares a moderate buy with a 17-cent target. That implies almost 85% upside potential, with the high-side target landing at 22 cents.



<h2>Saturn Oil &amp; Gas (OILSF)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/03/oilandgasstocks1600-300x169.png" alt="Panorama of Oil and Gas central processing platform in twilight, offshore hard work occupation twenty four working hours. Best oil stocks to buy"><div>Source: Oil and Gas Photographer / Shutterstock.com</div></div>


Based in Calgary, Alberta, Canada, Saturn Oil &amp; Gas (OTCMKTS:<a href="https://investorplace.com/stock-quotes/oilsf-stock-quote/">OILSF</a>) is a resource company engaged in the business of acquisition, exploration and development of petroleum and natural gas resource despoits in Western Canada. Further, the company&rsquo;s current focus is to advance the exploration and development of its oil and gas properties in Alberta and Saskatchewan.



As an upstream player in the hydrocarbon space, Saturn might not seem particularly relevant. Late last year, many oil-producing nations <a href="https://www.cnn.com/2023/11/30/energy/saudi-arabia-extend-production-cut-opec/index.html">agreed to cut production in a bid to bolster prices</a>. However, that effort did not succeed. Also, Reuters recently reported that rising U.S. oil production has <a href="https://www.reuters.com/markets/commodities/rising-us-oil-production-frustrates-opec-cuts-kemp-2024-02-01/">frustrated the aforementioned oil producers</a>. So, it seems OILSF could be one of the losing OTC stocks.



However, the blowout <a href="https://finance.yahoo.com/news/january-jobs-report-us-economy-adds-353000-jobs-blowing-past-wall-street-expectations-133251408.html">January jobs report</a> suggests that we shouldn&rsquo;t quite give up on black gold just yet. More people with jobs should translate to more resource consumption. And to be blunt, renewable energy just won&rsquo;t be enough to feed the growing demand profile. Notably, Echelon Wealth Partners believes OILSF <a href="https://www.tipranks.com/stocks/oilsf/forecast">could hit $4.22 per share or 137% up</a>.



<h2>Vivos (RDGL)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/medical-bills-1600-300x169.png" alt="Doctor or physician calculating a patients medical bills at a desk. Medical bills, health costs, health expenses."><div>Source: THICHA SATAPITANON / Shutterstock</div></div>


Before discussing radiation oncology medical device firm Vivos (OTCMKTS:<a href="https://investorplace.com/stock-quotes/rdgl-stock-quote/">RDGL</a>), it&rsquo;s important to disclose that I own RDGL stock. Please make a decision based on your own due diligence and a sober reflection of your risk tolerance. This is a security that has already lost almost 28% YTD and is likely subject to severe market turbulence.



With the caveats out of the way, Vivos is engaged in the development of its <a href="https://www.radiogel.com">yttrium-90-based brachytherapy device, RadioGel</a>, for the treatment of non-resectable tumors. According to Johns Hopkins Medicine, brachytherapy is a <a href="https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/brachytherapy">radiation treatment</a> that is given directly into the patient&rsquo;s body. Typically, the radiation is deployed using tiny devices such as wires, seeds, or rods filled with radioactive materials.



Where Vivos distinguishes itself is that RadioGel utilizes an injectable particle-gel, which delivers a very high local radiation dose. More broadly, RDGL entices speculators because the underlying industry is still in its early innings, <a href="https://www.grandviewresearch.com/industry-analysis/brachytherapy-devices-market">worth $907.76 million in 2022</a>.



As for a price target, it&rsquo;s difficult to say as no analyst currently covers RDGL. However, <a href="https://upperdeckoptions.com/2024/01/31/rdgl-stock-a-potential-sentiment-shift-in-2023/">based on my personal research</a>, I believe around 5 cents is the bottom.



<a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a>



On Penny Stocks and Low-Volume Stocks:&nbsp;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&nbsp;<a href="http://investorplace.com/">InvestorPlace.com</a>&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&nbsp;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">How to Profit Without Getting Scammed</a>



On the date of publication, Josh Enomoto&nbsp;held a LONG position in&nbsp;RDGL. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/02/high-risk-high-reward-7-otc-stocks-that-could-make-you-rich-this-year/">High-Risk, High-Reward: 7 OTC Stocks That Could Make You Rich This Year</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

High-Risk, High-Reward: 7 OTC Stocks That Could Make You Rich This Year

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
If you want millionaire-maker stocks, go consult Warren Buffett. The Oracle of Omaha has plenty of compelling ideas. However, if you want to reach millionaire status quickly, you&rsquo;re going to need to dial up the risk factor.



Here, the narrative is quite simple. If you want to give yourself a realistic possibility &ndash; note I didn&rsquo;t say probability &ndash; of winning big, you&rsquo;ve got to target extremely speculative market ideas. Usually, that means <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> or shares that are priced so low they can benefit from the law of small numbers.



However, once the initial liftoff is achieved, the beneficiary enterprises need attractive businesses to keep the fire burning. Arguably, the below companies have exactly that &ndash; but you better be prepared for extreme volatility. On that note, take a look at these millionaire-maker stocks.



<h2>Knightscope (KSCP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/kscp-stock-300x169.png" alt="An image of a Knightscope, Inc. (KSCP) robot in a parking garage"><div>Source: Sundry Photography / Shutterstock.com</div></div>Billed as a security camera and robotics firm, Knightscope (NASDAQ:<a href="https://investorplace.com/stock-quotes/kscp-stock-quote/">KSCP</a>) designs, builds, and deploys robots called <a href="https://www.knightscope.com">Autonomous Data Robots</a>. This solution allows for the monitoring of people in malls, parking lots, neighborhoods, and other public areas. Fundamentally, the main positive catalyst for KSCP stock centers on security.



As a Californian, one news item caught my eye: the popular In-N-Out Burger will <a href="https://apnews.com/article/oakland-innout-burger-closing-crime-9cd8f43eb43fe781086b9e277eb0724d#:~:text=January%2026%2C%202024-,OAKLAND%2C%20Calif.,only%20restaurant%20in%20Oakland%2C%20California.">close its first location</a> in its 75-year history in Oakland. To the chagrin of residents, a wave of car break-ins, property damage, theft, and robberies affecting both customers and employees took their toll on the business. It&rsquo;s incidents like this multiplied at a scale that demonstrates the forward viability of KSCP as one of the millionaire-maker stocks.



To be sure, Knightscope carries significant risks, including <a href="https://www.gurufocus.com/stock/KSCP/analysis/warning-signs">several severe ones</a>, per investment data aggregator Gurufocus. Still, after a rough patch in getting the business moving, the company has printed encouraging <a href="https://www.gurufocus.com/stock/KSCP/financials">revenue growth</a> recently.



<a href="https://www.businesswire.com/news/home/20240104703804/en/Ascendiant-Capital-Markets-Maintains-Buy-Rating-for-Knightscope-Raises-Per-Share-Price-Target-to-4.00">Ascendiant&rsquo;s Edward Woo believes shares can hit $4</a>. If so, we&rsquo;re talking upside potential of over 692%.



<h2>Quantum Computing (QUBT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/09/quantum-computing-3-300x169.jpg" alt="A concept image showing a quantum computer with a matrix background; quantum computing. leading quantum stocks, quantum computing stocks to buy"><div>Source: Shutterstock</div></div>I love companies that explain what they do just with their title. Here on this list of millionaire-maker stocks, we have Quantum Computing (NASDAQ:<a href="https://investorplace.com/stock-quotes/qubt-stock-quote/">QUBT</a>). It doesn&rsquo;t get much more direct than that. In all seriousness, the company is pioneering the production of photonic hardware solutions using non-linear quantum optics. This innovation should allow exponential acceleration in computing, machine learning, cybersecurity and other advanced fields.



According to Fortune Business Insights, the market itself is relatively small, landing at only $928.8 million last year. However, it&rsquo;s expanding at a tremendous clip; a compound annual growth rate (CAGR) of 32.1% to 2030, per analysts&rsquo; projections. If that rate holds true, the quantum computing sector <a href="https://www.fortunebusinessinsights.com/quantum-computing-market-104855#:~:text=The%20quantum%20computing%20market%20size,share%20of%2042.97%25%20in%202022.">could be worth approximately $6.53 billion</a>.



For context, QUBT stock only printed a market capitalization of just under $59 million. So, if the stars align, Quantum could easily rank among the millionaire-maker stocks.



Sure enough, <a href="https://finance.yahoo.com/news/7-analyst-backed-stocks-promising-000957206.html">Ascendiant&rsquo;s Woo also endorses QUBT, targeting $8.75</a> or around 1,015% up from Wednesday&rsquo;s close.



<h2>Vivos (RDGL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biomedical-technology1600-300x169.png" alt="Modern Medical Research Laboratory with Computer, Microscope, Glassware with Biochemicals on the Desk. Scientific Lab Biotechnology Development Center Full of High-Tech Equipment. Biomedical technology stocks, RSLS Stock"><div>Source: Gorodenkoff / Shutterstock.com</div></div>If you want to know what a dedicated fanbase for a publicly traded security looks like, <a href="https://twitter.com/EnomotoMedia">check out my X account</a>. Here, you&rsquo;re going to find plenty of discussions and expressions of adoration for medical technology firm Vivos (OTCMKTS:<a href="https://investorplace.com/stock-quotes/rdgl-stock-quote/">RDGL</a>). Yes, it&rsquo;s traded over the counter. Yes, it&rsquo;s a six-cent stock. No, it&rsquo;s not something out of the movie &ldquo;The Wolf of Wall Street.&rdquo;



Instead, what we have here is a radiation oncology specialist. Focusing on an advanced form of brachytherapy, Vivos utilizes radioactive materials (yttrium-90) to directly implement a high-dose treatment to the target area while imposing a minimal dosage to surrounding healthy tissue. Brachytherapy is already a promising therapeutic approach, which should see a 7.1% CAGR <a href="https://www.grandviewresearch.com/industry-analysis/brachytherapy-devices-market">to land at a value of $1.62 billion by 2030</a>.



Here&rsquo;s what&rsquo;s really intriguing about Vivos: it improves upon brachytherapy through a minimally invasive procedure that leverages a hydrogel solution to deliver the cancer-fighting therapeutic. Following the implementation, the hydrogel is safely absorbed by the body. Vivos appears unique in its brachytherapy-based approach. Therefore, I have personally put my money where my mouth is here.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.



Read More:&#8239;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">Penny Stocks &mdash;&nbsp;How to Profit Without Getting Scammed</a>



On the date of publication, Josh Enomoto&nbsp;held a LONG position in RDGL. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/02/3-stocks-to-turn-1000-into-1-million-february-2024/">3 Stocks to Turn $1,000 Into $1 Million: February 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Stocks to Turn $1,000 Into $1 Million: February 2024

Vivos Inc (RDGL) has issued an update. Vivos, Inc. has renewed its Executive Employment Agreement with CEO Dr. Michael Korenko, effective January 1...

Vivos Inc Secures Leadership Continuity with CEO Contract Renewal

Catalyst Watch: Disney earnings, Apple iPad event and Fed speakers back on the circuit

AAPL

ABNB

AMCX

ASCUF

AZTR

BYDDF

BYND

CABA

CPNG

CPRI

CRSP

DCPH

DDOG

EDIT

FGEN

KNSL

KOPN

KSCP

LAZR

MBLY

MCBC

MNST

MSFT

NDAQ

NISTF

NKLA

NRGV

OILSF

PENMF

PLTR

QUBT

QUISF

RACE

RBLX

RDDT

REGN

RIVN

SAVE

SHOP

SNAP

TCEHY

TSLA

UBER

UPST

USFD

VRTX

VSTO

VZIO

XIACF

ZYXI

Press Releases

Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation

Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials

Vivos Inc. Provides IDE Submission Status Update – Conversion to Pre-Sub Filing Accepted by the FDA

Vivos Inc. Extended its IsoPet® Precision Radionuclide TherapyTM to Exotics

Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM

Vivos

Comments

Vivos

Vivos (RDGL) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga